In today's Pharmaceutical Executive Daily, Parabilis Medicines prices a record-breaking $670 million IPO, Swedish biotech ...

We have entered a new era, with artificial intelligence (AI) driving one of the fastest technological transformations in ...

In today's Pharmaceutical Executive Daily, a pharma funding roundup covers two RNA-focused biotechs that secured fresh ...

Venture capital, long the dominant engine of drug development, was never really built for rare disease. The returns simply don’t scale to the fund sizes venture capitalists need to justify the effort.

ACD680 modulates gamma-secretase to lower Aβ42 production and increase Aβ37/Aβ38, potentially reducing aggregation and plaque formation via upstream amyloid processing rather than plaque clearance.

Parabilis raised $670M via 33.5M shares at $20 and secured $75M Regeneron private placement at $18, totaling ~$745M gross proceeds ahead of Nasdaq listing. Helicon discovery platform engineers ...

Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...

The ACCESS Model’s significance for the industry is that it introduces a new level of operational capacity to what remains ...

Transaction terms include a $124/share all-cash tender offer, implying a 40% premium to prior close, with expected Q3 2026 closing pending antitrust and customary conditions. Regulatory timelines ...

Contributing factors include genetic predisposition, stress, nutritional deficiencies, autoimmune or thyroid disorders, ...

FDA’s draft guidance allows sponsors to leverage public and platform knowledge for CMC, nonclinical, and clinical support of ...

Under the terms of the agreement, Alnylam will provide $30 million in upfront consideration, including cash and an equity ...